‘007-030-00-3,nitric acid …% [C ≤ 70 %],231-714-2,7697-37-2., Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A , H272 H331 H314 , GHS03 GHS06 GHS05 Dgr , H272 H331 H314 ,EUH071, Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % ,B’, ‘014-048-00-5,silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1),206-991-8, 409-21-2 308076-74-6 ,Carc. 1B,H350i, GHS08 Dgr ,H350i’,,,, ‘014-049-00-0,trimethoxyvinylsilane; trimethoxy(vinyl)silane,220-449-8,2768-02-7,Skin Sens. 1B,H317, GHS07 Wng ,H317’,,,, ‘014-050-00-6, tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane ,213-934-0,1067-53-4,Repr. 1B,H360FD, GHS08 Dgr ,H360FD’,,,, ‘016-098-00-3,dimethyl disulphide,210-871-0,624-92-0, Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410 , GHS02 GHS06 GHS08 GHS09 Dgr , H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410 ,, inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10’ ,, ‘029-024-00-X, granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] ,231-159-6,7440-50-8,Aquatic Chronic 2,H411,GHS09,H411’,,,, ‘029-025-00-5, bis( N -hydroxy- N -nitrosocyclohexylaminato- O , O ’)copper; bis( N -cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] ,239-703-4, 312600-89-8 15627-09-5 , Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H228 H302 H373 (liver) H318 H400 H410 , GHS02 GHS07 GHS08 GHS05 GHS09 Dgr , H228 H302 H373(liver) H318 H410 ,, oral: ATE = 360 mg/kg bw M = 1 M = 1’ ,, ‘050-031-00-9, dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] ,222-883-3 [1] 293-901-5 [2],3648-18-8 [1] 91648-39-4 [2], Repr. 1B STOT RE 1 , H360D H372 (immune system) , GHS08 Dgr , H360D H372 (immune system)’ ,,,, ‘601-092-00-0, dibenzo[ def , p ]chrysene; dibenzo[ a , l ]pyrene ,205-886-4,191-30-0, Carc. 1B Muta. 2 , H350 H341 , GHS08 Dgr , H350 H341 ,,Carc. 1B; H350: C ≥ 0,001 %’,, ‘603-237-00-3, ipconazole (ISO); (1 RS ,2 SR ,5 RS ;1 RS ,2 SR ,5 SR )-2-(4-chlorobenzyl)-5-isopropyl-1-(1 H -1,2,4-triazol-1-ylmethyl)cyclopentanol ,-, 125225-28-7 115850-69-6 115937-89-8 , Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 , H360D H302 H373 (eyes, skin, liver) H410 , GHS08 GHS07 GHS09 Dgr , H360D H302 H373 (eyes, skin, liver) H410 ,, oral: ATE = 500 mg/kg bw M = 100’ ,, ‘603-238-00-9,bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme,205-594-7,143-24-8,Repr. 1B,H360FD, GHS08 Dgr ,H360FD’,,,, ‘603-239-00-4, paclobutrazol (ISO); (2 RS ,3 RS )-1-(4-chlorophenyl)-4,4-dimethyl-2-(1 H -1,2,4-triazol-1-yl)pentan-3-ol ,-,76738-62-0, Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 , H361d H332 H302 H319 H400 H410 , GHS08 GHS07 GHS09 Wng , H361d H332 H302 H319 H410 ,, inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10’ ,, ‘603-240-00-X,2,2-bis(bromomethyl)propane-1,3-diol,221-967-7,3296-90-0, Carc. 1B Muta. 1B , H350 H340 , GHS08 Dgr , H350 H340’ ,,,, ‘603-241-00-5, geraniol; (2 E )-3,7-dimethylocta-2,6-dien-1-ol ,203-377-1,106-24-1,Skin Sens. 1,H317, GHS07 Wng ,H317’,,,, ‘605-041-00-3,2-(4- tert -butylbenzyl)propionaldehyde,201-289-8,80-54-6,Repr. 1B,H360Fd, GHS08 Dgr ,H360Fd’,,,, ‘607-738-00-8, MCPA-thioethyl (ISO); S -ethyl (4-chloro-2-methylphenoxy)ethanethioate; S -ethyl 4-chloro- o -tolyloxythioacetate ,246-831-4,25319-90-8, Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 , H302 H373 (liver) H400 H410 , GHS07 GHS08 GHS09 Wng , H302 H373 (liver) H410 ,, oral: ATE = 450 mg/kg bw M = 10 M = 10’ ,, ‘607-740-00-9,diisooctyl phthalate,248-523-5,27554-26-3,Repr. 1B,H360FD, GHS08 Dgr ,H360FD’,,,, ‘607-741-00-4,4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5 H )-one; flupyradifurone,-,951659-40-8, Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H302 H373 (muscle) H400 H410 , GHS07 GHS08 GHS09 Wng , H302 H373 (muscle) H410 ,, oral: ATE = 500 mg/kg bw M = 10 M = 10’ ,, ‘607-742-00-X, thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate ,-,317815-83-1, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1000 M = 1000’ ,, ‘607-743-00-5, L-(+)-lactic acid; (2 S )-2-hydroxypropanoic acid ,201-196-2,79-33-4, Skin Corr. 1C Eye Dam. 1 , H314 H318 , GHS05 Dgr ,H314,EUH071’,,, ‘607-744-00-0,2-methoxyethyl acrylate,221-499-3,3121-61-7, Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 , H226 H341 H360FD H331 H302 H314 H318 H317 , GHS02 GHS05 GHS06 GHS08 Dgr , H226 H341 H360FD H331 H302 H314 H317 ,EUH071, inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw’ ,, ‘607-745-00-6,glyoxylic acid …%,206-058-5,298-12-4, Eye Dam. 1 Skin Sens. 1B , H318 H317 , GHS05 GHS07 Dgr , H318 H317 ,,,B’, ‘607-746-00-1, sodium N -(hydroxymethyl)glycinate; [formaldehyde released from sodium N -(hydroxymethyl)glycinate] ,274-357-8,70161-44-3, Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 , H350 H341 H332 H302 H335 H315 H319 H317 , GHS08 GHS07 Dgr , H350 H341 H332 H302 H335 H315 H319 H317 ,, inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw , 8 9’ , ‘611-181-00-6, potassium (oxido- NNO -azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] ,-,66603-10-9, Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 , H228 H301 H373 (liver) H315 H318 H411 , GHS02 GHS06 GHS08 GHS05 GHS09 Dgr , H228 H301 H373 (liver) H315 H318 H411 ,,oral: ATE = 136 mg/kg bw’,, ‘612-294-00-3, mecetronium etilsulfate; N -ethyl- N , N -dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES] ,221-106-5,3006-10-8, Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H314 H318 H400 H410 , GHS05 GHS09 Dgr , H314 H410 ,EUH071, M = 100 M = 1000’ ,, ‘613-331-00-6, (2 RS )-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1 H -1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole ,-,1417782-03-6, Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H317 H400 H410 , GHS07 GHS09 Wng , H317 H410 ,, M = 1 M = 1’ ,, ‘613-332-00-1, oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1 H -pyrazol-1-yl]ethanone ,-,1003318-67-9,Aquatic Chronic 1,H410, GHS09 Wng ,H410,,M = 1’,, ‘613-333-00-7,pyrithione zinc; ( T -4)-bis[1-(hydroxy-.kappa. O )pyridine-2(1 H )-thionato-.kappa. S ]zinc,236-671-3,13463-41-7, Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H301 H372 H318 H400 H410 , GHS08 GHS06 GHS05 GHS09 Dgr , H360D H330 H301 H372 H318 H410 ,, inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10’ ,, ‘613-334-00-2, flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one ,262-661-3,61213-25-0, Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H360FD H302 H317 H400 H410 , GHS08 GHS07 GHS09 Dgr , H360FD H302 H317 H410 ,, oral: ATE = 500 mg/kg bw M = 100 M = 100’ ,, ‘613-335-00-8,4,5-dichloro-2-octyl-2 H -isothiazol-3-one; [DCOIT],264-843-8,64359-81-5, Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 , H330 H302 H314 H318 H317 H400 H410 , GHS06 GHS05 GHS09 Dgr , H330 H302 H314 H317 H410 ,EUH071, inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ ,, ‘613-336-00-3, 2-methyl-1,2-benzothiazol-3(2 H )-one; [MBIT] ,-,2527-66-4, Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 , H312 H301 H314 H318 H317 H400 H411 , GHS06 GHS05 GHS09 Dgr , H312 H301 H314 H317 H410 ,EUH071, dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1’ ,, ‘616-228-00-4, 3-(difluoromethyl)-1-methyl- N -(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad ,-,907204-31-3, Lact. Aquatic Acute 1 Aquatic Chronic 1 , H362 H400 H410 , GHS09 Wng , H362 H410 ,, M = 1 M = 1’ ,, ‘616-230-00-5, N -(hydroxymethyl)acrylamide; methylolacrylamide; [NMA],213-103-2,924-42-5, Carc. 1B Muta. 1B STOT RE 1 , H350 H340 H372 (peripheral nervous system) , GHS08 Dgr , H350 H340 H372 (peripheral nervous system)’ ,,,, ‘616-231-00-0, 5-fluoro-1,3-dimethyl- N -[2-(4-methylpentan-2-yl)phenyl]-1 H -pyrazole-4-carboxamide; 2'-[( RS )-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen ,-,494793-67-8, Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H400 H410 , GHS08 GHS09 Wng , H351 H410 ,, M = 1 M = 1’ ,, ‘616-232-00-6, iprovalicarb (ISO); isopropyl [(2 S )-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate ,-,140923-17-7,Carc. 2,H351, GHS08 Wng ,H351’,,,, ‘616-233-00-1, silthiofam (ISO); N -allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide ,-,175217-20-6, STOT RE 2 Aquatic Chronic 2 , H373 H411 , GHS08 GHS09 Wng , H373 H411’ ,,,, ‘650-057-00-6,Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide],283-644-7,84696-25-3,Aquatic Chronic 3,H412,,H412’,,,, ‘007-004-00-1,nitric acid …% [C > 70 %],231-714-2,7697-37-2, Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A , H272 H330 H314 , GHS03 GHS06 GHS05 Dgr , H272 H330 H314 ,EUH071, Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % ,B’, ‘014-018-00-1, octamethylcyclotetrasiloxane; [D4] ,209-136-7,556-67-2, Repr. 2 Aquatic Chronic 1 , H361f *** H410 , GHS08 GHS09 Wng , H361f *** H410 ,,M = 10’,, ‘015-134-00-5, pirimiphos-methyl (ISO); O -[2-(diethylamino)-6-methylpyrimidin-4-yl] O , O -dimethyl phosphorothioate ,249-528-5,29232-93-7, Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H302 H372 (nervous system) H400 H410 , GHS07 GHS08 GHS09 Dgr , H302 H372 (nervous system) H410 ,, oral: ATE = 1414 mg/kg bw M = 1000 M = 1000’ ,, ‘015-181-00-1,phosphine,232-260-8,7803-51-2, Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 , H220 H330 H314 H400 , GHS02 GHS04 GHS06 GHS05 GHS09 Dgr , H220 H330 H314 H400 ,, inhalation: ATE = 10 ppmV (gases) ,U’, ‘050-021-00-4,dichlorodioctylstannane,222-583-2,3542-36-7, Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 , H360D H330 H372 ** H412 , GHS08 GHS06 Dgr , H360D H330 H372 ** H412 ,, Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists)’ ,, ‘050-027-00-7,2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE],239-622-4,15571-58-1, Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H372 (immune system) H400 H410 , GHS08 GHS09 Dgr , H360D H372 (immune system) H410’ ,,,, ‘082-013-00-1,lead powder; [particle diameter < 1 mm],231-100-4,7439-92-1, Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 , H360FD H362 H400 H410 , GHS08 GHS09 Dgr , H360FD H362 H410 ,, Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10’ ,, ‘603-014-00-0, 2-butoxyethanol; ethylene glycol monobutyl ether ,203-905-0,111-76-2, Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 , H332 H302 H315 H319 , GHS07 Wng , H332 H302 H315 H319 ,,oral: ATE = 1200 mg/kg bw’,, ‘603-065-00-9, m -bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether ,202-987-5,101-90-6, Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 , H350 H341 H311 H302 H315 H319 H317 H412 , GHS08 GHS06 Dgr , H350 H341 H311 H302 H315 H319 H317 H412 ,,dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’,, ‘607-177-00-9, tribenuron-methyl (ISO); methyl 2-[ N -(4-methoxy-6-methyl-1,3,5-triazin-2-yl)- N -methylcarbamoylsulfamoyl]benzoate ,401-190-1,101200-48-0, STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H373 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H373 H317 H410 ,, M = 100 M = 100’ ,, ‘607-256-00-8, azoxystrobin (ISO); methyl ( E )-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate ,-,131860-33-8, Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 , H331 H400 H410 , GHS06 GHS09 Dgr , H331 H410 ,, inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10’ ,, ‘607-314-00-2, ethofumesate (ISO); ( RS )-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate ,247-525-3,26225-79-6, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 M = 1’ ,, ‘609-041-00-4,2,4-dinitrophenol,200-087-7,51-28-5, Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 , H331 H311 H300 H372 H400 , GHS06 GHS08 GHS09 Dgr , H331 H311 H300 H372 H400 ,,dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’,, ‘609-064-00-X, mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione ,-,104206-82-8, Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H361d H373 (eyes, nervous system) H400 H410 , GHS08 GHS09 Wng , H361d H373 (eyes, nervous system) H410 ,, M = 10 M = 10’ ,, ‘613-112-00-5, octhilinone (ISO); 2-octyl-2 H -isothiazol-3-one; [OIT] ,247-761-7,26530-20-1, Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 , H330 H311 H301 H314 H318 H317 H400 H410 , GHS06 GHS05 GHS09 Dgr , H330 H311 H301 H314 H317 H410 ,EUH071, inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ ,, ‘613-115-00-1, hymexazol (ISO); 3-hydroxy-5-methylisoxazole ,233-000-6,10004-44-1, Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 , H361d H302 H318 H317 H411 , GHS08 GHS07 GHS05 GHS09 Dgr , H361d H302 H318 H317 H411 ,,oral: ATE = 1600 mg/kg bw’,, ‘613-125-00-6, hexythiazox (ISO); trans -5-(4-chlorophenyl)- N -cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide ,-,78587-05-0, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 M = 1’ ,, ‘613-202-00-4, pymetrozine (ISO); ( E )-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2 H )-one ,-,123312-89-0, Carc. 2 Repr. 2 Aquatic Chronic 1 , H351 H361fd H410 , GHS08 GHS09 Wng , H351 H361fd H410 ,,M = 1’,, ‘613-259-00-5, imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1 R )- cis -chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1 R )- trans -chrysanthemate ,428-790-6,72963-72-5, Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410 , GHS08 GHS07 GHS09 Wng , H351 H332 H302 H371 (nervous system; oral, inhalation) H410 ,, inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10’ ,, ‘616-014-00-0,butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime,202-496-6,96-29-7, Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 , H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 , GHS08 GHS06 GHS05 Dgr , H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 ,,dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’,, ‘617-006-00-X,bis(α,α-dimethylbenzyl) peroxide,201-279-3,80-43-3, Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2 , H242 H360D H315 H319 H411 , GHS02 GHS08 GHS07 GHS09 Dgr , H242 H360D H315 H319 H411’ ,,,,